TY  - JOUR
AU  - Kravchenko, Kateryna
AU  - Kulawik, Andreas
AU  - Hülsemann, Maren
AU  - Kühbach, Katja
AU  - Zafiu, Christian
AU  - Herrmann, Yvonne
AU  - Linnartz, Christina
AU  - Peters, Luriano
AU  - Bujnicki, Tuyen
AU  - Willbold, Johannes
AU  - Bannach, Oliver
AU  - Willbold, Dieter
TI  - Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay
JO  - Biological chemistry
VL  - 398
IS  - 4
SN  - 1437-4315
CY  - Berlin [u.a.]
PB  - de Gruyter
M1  - FZJ-2016-06524
SP  - 465–475
PY  - 2017
AB  - Early diagnostics at the preclinical stage of Alzheimer’s disease is of utmost importance for drug development in clinical trials and prognostic guidance. Since soluble Aβ oligomers are considered to play a crucial role in the disease pathogenesis, several methods aim to quantify Aβ oligomers in body fluids such as cerebrospinal fluid (CSF) and blood plasma. The highly specific and sensitive method surface-based fluorescence intensity distribution analysis (sFIDA) has successfully been established for oligomer quantitation in CSF samples. In our study, we explored the sFIDA method for quantitative measurements of synthetic Aβ particles in blood plasma. For this purpose, EDTA, citrate and heparin treated blood plasma samples from five individual donors were spiked with Aβ coated silica nanoparticles (Aβ-SiNaPs) and were applied to the sFIDA assay. Based on the assay parameters linearity, coefficient of variation and limit of detection, we found that EDTA plasma yields the most suitable parameter values for quantitation of Aβ oligomers in sFIDA assay with a limit of detection of 16 fM.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000397610800005
C6  - pmid:27811340
DO  - DOI:10.1515/hsz-2016-0153
UR  - https://juser.fz-juelich.de/record/823892
ER  -